書誌情報

P6-5. Final analysis of single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM) in the DREAMM-2 trial : Encore
Ajay K. Nooka1, Adam Cohen2, Hans Lee3, Ashraf Badros4, Attaya Suvannasankha5, Natalie Callander6, Al-Ola Abdallah7, Suzanne Trudel8, Ajai Chari9, Edward Libby10, Hirofumi Nakano11, Maria Chaudhry12, Malin Hultcrantz13, K. Martin Kortum14, Paul Richardson15, Rakesh Popat16, Douglas Sborov17, Shawn Hakim18, Boris Gorsh18, Joanna Opalinska18, Sagar Lonial1
1Winship Cancer Institute of Emory University Hospital, 2Abramson Cancer Center, University of Pennsylvania, 3MD Anderson Cancer Center, 4University of Maryland School of Medicine, 5Indiana University Simon Cancer Center and Roudebush VAMC, 6Carbone Cancer Center, University of Wisconsin, 7University of Kansas, 8Princess Margaret Cancer Centre, 9Icahn School of Medicine at Mount Sinai, 10Division of Medical Oncology, University of Washington, 11GSK K.K., 12George Washington University, 13Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 14Universitatsklinikum Wurzburg, Medizinische Klinik II, 15Dana Farber Cancer Institute, 16University College London Hospitals, NHS Foundation Trust, 17Huntsman Cancer Institute, University of Utah, 18GSK, Upper Providence
International Journal of Myeloma 13(3): 166-166, 2023.
個人会員・法人会員の方(IDが5または10で始まる方)
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。